Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: J Immunol. 2012 Jul 23;189(5):2151–2158. doi: 10.4049/jimmunol.1103741

Figure 6.

Figure 6

Rapamycin enhances the ability of DCs to induce therapeutic anti-tumor immunity. (A) Mice inoculated with tumors on Day 0 were each immunized once subcutaneously with 5 × 105 DCs treated as indicated on Day 3 and then monitored every three days for tumor growth. Tumor volumes were measured at each time point. The kinetics of tumor growth for each individual mouse in the experiment (n = 10 per group) is plotted. 19 days after immunization, mice were sacrificed and tumors were excised, photographed (B) and tumor volume (C) and mass (D) were calculated. Data from all individual mice in the experiment are shown, and mean values illustrated by horizontal bars in (C) and (D). Asterisks show statistically significant differences (p<0.05). (E) Tumor single-cell suspensions were analyzed by FACS and the frequencies of Kb-OVA tetramer+ CD8+ T cells within the CD45+ gates are shown. Data are concatenated from all tumors for each mouse group. All tumor experiments were repeated at least three times with similar results.